TP53 and laryngeal carcinoma: As such, we identified a novel mechanism by which tumor immune evasion of laryngeal cancer is regulated by the PD-1/hsa-miR-128a/p53 axis, suggesting that hsa-miR-128a-based therapy may be a novel approach for laryngeal cancer treatment.